VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

IWWM-11 2022 | The safety and efficacy of MB-106 for the treatment of Waldenström’s macroglobulinemia

Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center, Seattle, WA, shares some insights into the safety and efficacy of MB-106 for the treatment of Waldenström’s macroglobulinemia (WM), and ongoing studies evaluating this novel CAR-T construct. This interview took place at the 11th International Workshop on Waldenström’s Macroglobulinemia (IWWM-11), held in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter